Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Redemption of Operating Partnership units for cash	Preferred Operating Partnership	Operating Partnership	Operating Partnership Redemption of Operating Partnership units for stock	Operating Partnership Redemption of Operating Partnership units for cash	Other	Common Stock	Common Stock Redemption of Operating Partnership units for stock	Additional Paid-in Capital	Additional Paid-in Capital Redemption of Operating Partnership units for stock	Additional Paid-in Capital Redemption of Operating Partnership units for cash	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2016	$ 2,596,166		$ 147,920	$ 203,354			$ 0	$ 1,259		$ 2,566,120			$ 16,770	$ (339,257)
Beginning balance (in shares) at Dec. 31, 2016								125,881,460
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon the exercise of options (in shares)	38,418							38,418
Issuance of common stock upon the exercise of options	$ 1,266									1,266
Restricted stock grants issued (in shares)								95,392
Restricted stock grants issued								$ 1		(1)
Restricted stock grants cancelled (in shares)								(8,179)
Compensation expense related to stock-based awards	9,561									9,561
Issuance of Operating Partnership units in conjunction with acquisitions	7,618			7,618
Redemption or purchase of noncontrolling interests		$ (2,510)				$ (1,238)						$ (1,272)
Issuance of Preferred D Units in the Operating Partnership in conjunction with acquisitions	11,161		11,161
Noncontrolling interest in consolidated joint venture	216						216
Repurchase of equity portion of 2013 exchangeable senior notes	(6,189)									(6,189)
Net income (loss)	514,222		14,989	20,317			(97)							479,013
Other comprehensive income (loss)	17,308		106	682									16,520
Distributions to Operating Partnership units held by noncontrolling interests	(31,972)		(14,540)	(17,432)
Dividends paid on common stock	(393,040)													(393,040)
Ending balance at Dec. 31, 2017	$ 2,723,807		159,636	213,301			119	$ 1,260		2,569,485			33,290	(253,284)
Ending balance (in shares) at Dec. 31, 2017								126,007,091
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon the exercise of options (in shares)	54,575							54,575
Issuance of common stock upon the exercise of options	$ 1,169									1,169
Restricted stock grants issued (in shares)								85,066
Restricted stock grants issued	1							$ 1
Restricted stock grants cancelled (in shares)								(11,771)
Issuance of common stock, net of offering costs (in shares)								933,789
Issuance of common stock, net of offering costs	90,231							$ 10		90,221
Compensation expense related to stock-based awards	11,176									11,176
Repayment of receivable for preferred operating units pledged as collateral on loan	495		495
Issuance of Operating Partnership units in conjunction with acquisitions	1,877			1,877
Redemption or purchase of noncontrolling interests		$ (2,558)			$ (1,337)	$ (1,126)					$ 1,337	$ (1,432)
Redemption or purchase of noncontrolling interests (in shares)								35,000
Conversion of Preferred C Units in the Operating Partnership for Common Operating Partnership Units			(6,851)	6,851
Noncontrolling interest in consolidated joint venture	122						122
Repurchase of equity portion of 2013 exchangeable senior notes	(31,251)									(31,251)
Net income (loss)	447,080		13,995	17,797			(1)							415,289
Other comprehensive income (loss)	1,430		12	58									1,360
Distributions to Operating Partnership units held by noncontrolling interests	(33,250)		(14,191)	(19,059)
Dividends paid on common stock	(424,907)													(424,907)
Ending balance at Dec. 31, 2018	$ 2,785,422		153,096	218,362			240	$ 1,271		2,640,705			34,650	(262,902)
Ending balance (in shares) at Dec. 31, 2018	127,103,750							127,103,750
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon the exercise of options (in shares)	211,057							211,057
Issuance of common stock upon the exercise of options	$ 3,063							$ 3		3,060
Restricted stock grants issued (in shares)								109,081
Restricted stock grants issued	2							$ 2
Restricted stock grants cancelled (in shares)								(8,863)
Issuance of common stock, net of offering costs (in shares)								1,779,200
Issuance of common stock, net of offering costs	198,827							$ 19		198,808
Compensation expense related to stock-based awards	13,051									13,051
Repayment of receivable for preferred operating units pledged as collateral on loan	1,211			1,211
Redemption or purchase of noncontrolling interests					$ (13,057)						$ 13,057
Redemption or purchase of noncontrolling interests (in shares)									340,182
Issuance of Preferred D Units in the Operating Partnership in conjunction with acquisitions	28,022		28,022
Conversion of Preferred C Units in the Operating Partnership for Common Operating Partnership Units			(4,374)	4,374
Noncontrolling interest in consolidated joint venture	173						173
Net income (loss)	451,123		12,492	18,711			(47)							419,967
Other comprehensive income (loss)	(66,843)		(407)	(2,820)									(63,616)
Distributions to Operating Partnership units held by noncontrolling interests	(34,243)		(12,881)	(21,362)
Dividends paid on common stock	(458,114)													(458,114)
Ending balance at Dec. 31, 2019	$ 2,921,694		$ 175,948	$ 205,419			$ 366	$ 1,295		$ 2,868,681			$ (28,966)	$ (301,049)
Ending balance (in shares) at Dec. 31, 2019	129,534,407							129,534,407